OncoMatch/Clinical Trials/NCT04813705

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

Is NCT04813705 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chemotherapy for nasopharyngeal carcinoma.

Phase 2RecruitingTaizhou HospitalNCT04813705Data as of May 2026

Treatment: Chemotherapy — The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage I, II, III, IVA

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiation therapy

Exception: non-melanomatous skin cancers outside intended RT treatment volume

History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).

Cannot have received: chemotherapy

Prior chemotherapy ... to primary tumor or nodes.

Cannot have received: surgery

Exception: diagnostic

Prior ... surgery (except diagnostic) to primary tumor or nodes.

Lab requirements

Blood counts

HGB≥90 g/L, ANC≥1.5×10^9/L, PLT≥80×10^9/L.

Kidney function

CCR≥60ml/min or Cr<1.5×ULN.

Liver function

ALT, AST <2.5 fold of ULN; TBIL <2.0×ULN.

HGB≥90 g/L，ANC≥1.5×10^9 /L，PLT≥80×10^9 /L. ALT,AST<2.5 fold of ULN；TBIL<2.0×ULN. CCR≥60ml/min or Cr<1.5×ULN.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify